Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease
Authors' conclusion
Teprotumumab introduction increased TED therapy evaluations, yet not all received recommended treatment due to safety concerns or accessibility issues. Enhancing collaborative care, medication accessibility, and adverse effect management is crucial.
Study context
- Population
- Patients with active, moderate to severe thyroid eye disease (TED) recommended for medical therapy, 3 referral centers, January 1, 2018, to December 30, 2022recommended medical therapy
- Participants
- 74 patients
- Exposure
- Before vs after teprotumumab availability
- Prior to teprotumumab availabilityn = 19reference
- After teprotumumab became availablen = 55
- Outcome
- Received medical therapy
Methodological detailsmulticentre (3 referral centers)
- Multicentre (3 referral centers)
Main finding
As reported in the abstract
| Group | Value | Corticosteroids | Tocilizumab | Teprotumumab | No medical therapy |
|---|---|---|---|---|---|
| Prior to teprotumumab availability | 100% | 14, 73.7% | 5, 26.3% | ||
| After teprotumumab became available | 74.6% | 5, 9.1% | 3, 5.4% | 33, 60% | 14, 25.4% |
Value
Prior to teprotumumab availability100%
After teprotumumab became available74.6%
Corticosteroids
Prior to teprotumumab availability14, 73.7%
After teprotumumab became available5, 9.1%
Tocilizumab
Prior to teprotumumab availability5, 26.3%
After teprotumumab became available3, 5.4%
Teprotumumab
Prior to teprotumumab availability— not stated in the abstract
After teprotumumab became available33, 60%
No medical therapy
Prior to teprotumumab availability— not stated in the abstract
After teprotumumab became available14, 25.4%
Observational data: associations, not effects.
Further findings
Collaborative recommendations from endocrinologists and ophthalmologists in a TED clinic
- Collaborative recommendations
- 53%
Reasons for discordance between recommendation and therapy received
- Patients' refusal
- 9, 64.3%
- Refusal due to side effect concerns
- 8, 88.9%
- Insurance denial
- 5, 35.7%
Safety
Adverse effects by treatment
- Teprotumumab: otic changes
- 10, 30.3%
- Teprotumumab: weight loss
- 9, 27.3%
- Teprotumumab: hyperglycemia
- 6, 18.2%
- Teprotumumab: serious infections
- 2 (6.1%)
- Corticosteroids: insomnia
- 4, 21.1%
- Tocilizumab: infusion reaction requiring hospitalization
- 1 patient
Original publication
Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease. Endocr Pract. Published 25 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →